PCVX · Vaxcyte, Inc. · Metrics
$56.48
+0.43 (+0.77%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$8.36B
Shares
148.81M
Volume · Oct 2
2.4M
Avg daily vol (3M)
1.15M
PCVX metrics
54 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$56.48
Market cap
$8.36B
Price action
20 metricsPrice change (1W)
+0.5%
Price change (30D)
-7.7%
Price change (3M)
-3.3%
Price change (6M)
-3.3%
Price change (YTD)
+22.4%
Price change (1Y)
+40.7%
Trailing year
Price change (5Y)
+115.3%
52-week high
$63.30
52-week low
$40.13
Change from 52-week high
-10.8%
Change from 52-week low
+40.7%
Annualized volatility
44.5%
Annualized volatility (3M)
38.5%
Beta
0.9
RSI (14D)
42.8
Price vs SMA 50
-3.5%
Price vs SMA 200
+2.4%
Avg volume (3M)
1.15M
Relative volume
2.1
Average dollar volume
$67.30M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
148.81M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.0
reciprocal yield 33.0%
FCF yield
-10.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-12.7%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-05-06
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$1.17B
Net income (TTM)
−$1.06B
Trailing 12 months
Diluted EPS (TTM)
$-7.64
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+6.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-38.6%
Return on assets
-33.9%
Debt / equity
—
Current ratio
5.7
EBITDA (TTM)
—
Free cash flow (TTM)
−$894.14M
Quick ratio
5.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.49B
Latest balance sheet
Cash & equivalents
$183.19M
Total assets
$3.14B
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$881.23M
Capital expenditures (TTM)
$12.90M
R&D (TTM)
$1.03B
SG&A (TTM)
—
Stock compensation (TTM)
$150.51M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
336
13F filer change QoQ
-3
Institutional ownership
116.2%
Short interest
3 metricsShort interest
10.8%
Latest settlement · 13.0 days to cover
Days to cover
13.0d
Short-squeeze score
82 / 100
Insider activity
2 metricsNet insider buying (90D)
−$3.68M
Insider-sentiment score
48 / 100
Risk flags
1 metricsGoing concern
—